{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:47:40Z","timestamp":1775152060528,"version":"3.50.1"},"reference-count":0,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Infectious Diseases and Medical Microbiology"],"published-print":{"date-parts":[[2005,1]]},"abstract":"<jats:p>Infliximab, a monoclonal antibody directed against tumour necrosis factor\u2010alpha, is an effective therapy for Crohn\u2032s disease. Though uncommon, serious opportunistic infections, including reactivation of tuberculosis, have occurred in patients after infliximab administration. Meningitis caused by <jats:italic>Listeria monocytogenes<\/jats:italic> developed in a 37\u2010year\u2010old man six days after the second infusion of infliximab. The patient, who also was treated with azathioprine and corticosteroids, had an uneventful recovery after a course of antibiotics. Several other recent reports have implicated infliximab therapy in the development of severe <jats:italic>Listeria<\/jats:italic> infections, particularly meningitis and sepsis. With the increasing use of tumour necrosis factor\u2010alpha\u2010neutralizing agents, clinicians should be aware of the risk of opportunistic infections caused by <jats:italic>L monocytogenes<\/jats:italic> in patients with Crohn\u2032s disease following infliximab treatment.<\/jats:p>","DOI":"10.1155\/2005\/814698","type":"journal-article","created":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T08:05:12Z","timestamp":1458029112000},"page":"289-292","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Listeria Meningitis Complicating Infliximab Treatment for Crohn\u2019s Disease"],"prefix":"10.1155","volume":"16","author":[{"given":"Geoffrey","family":"Williams","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asad A","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franzjosef","family":"Schweiger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,3,16]]},"container-title":["Canadian Journal of Infectious Diseases and Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/cjidmm\/2005\/814698.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/2005\/814698","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T10:24:59Z","timestamp":1723112699000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/2005\/814698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["10.1155\/2005\/814698"],"URL":"https:\/\/doi.org\/10.1155\/2005\/814698","archive":["Portico"],"relation":{},"ISSN":["1712-9532","1918-1493"],"issn-type":[{"value":"1712-9532","type":"print"},{"value":"1918-1493","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1]]},"assertion":[{"value":"2005-03-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}